Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $230.3 million.

  • Coherus Oncology's Cash from Investing Activities fell 15241.22% to -$67.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $377.4 million, marking a year-over-year increase of 41.84%. This contributed to the annual value of $230.3 million for FY2024, which is 59.24% up from last year.
  • According to the latest figures from FY2024, Coherus Oncology's Cash from Investing Activities is $230.3 million, which was up 59.24% from $144.6 million recorded in FY2023.
  • Coherus Oncology's Cash from Investing Activities' 5-year high stood at $230.3 million during FY2024, with a 5-year trough of -$166.8 million in FY2022.
  • In the last 3 years, Coherus Oncology's Cash from Investing Activities had a median value of $144.6 million in 2023 and averaged $69.4 million.
  • Per our database at Business Quant, Coherus Oncology's Cash from Investing Activities tumbled by 861.11% in 2021 and then soared by 186.69% in 2023.
  • Yearly analysis of 5 years shows Coherus Oncology's Cash from Investing Activities stood at -$14.4 million in 2020, then crashed by 861.11% to -$138.4 million in 2021, then fell by 20.55% to -$166.8 million in 2022, then soared by 186.69% to $144.6 million in 2023, then soared by 59.24% to $230.3 million in 2024.